

Techno-Hell: Pfizer mRNA Flu Shots Soon to Hit Pharmacies Worldwide

By [Ben Bartee](#)
Global Research, July 28, 2023

Region: [USA](#)
Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the Translate Website button below the author's name.

To receive Global Research's Daily Newsletter (selected articles), [click here](#).

Click the share button above to email/forward this article to your friends and colleagues. Follow us on [Instagram](#) and [Twitter](#) and subscribe to our [Telegram Channel](#). Feel free to repost and share widely Global Research articles.

The benevolent multinational technocratic overlords at Pfizer, assisted of course by the magnanimous Public Health™ authorities in the United States and throughout the West, are excited to introduce mRNA flu shots, seeing as how the mRNA COVID-19 injections have performed so admirably over the past two and a half years.

Via [Pfizer](#):

"In September 2022, Pfizer began recruiting volunteers to participate in its Phase 3 clinical trial for that mRNA flu vaccine candidate. The hope, says McLaughlin, is that **scientists can develop a flu vaccine faster**, and with more accurate strain matching with in-season circulating strains **than those currently available**. One that may also spark a more robust immune response.

"As these viruses continue to adapt, what really matters is how well your vaccine matches what strains are currently circulating," says McLaughlin. "And **the speed with which you can keep up with that determines the success of a vaccination program.**"

Eerily reminiscent of "Operation Warp Speed," no?

The National Institutes of Health bureaucrats are also eager beavers to get their biotech into the arms of every American man, woman, child, and baby. Because they care.

Via [NIH](#):

"A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases' (NIAID) Vaccine Research Center (VRC), part of the National Institutes of Health, has begun enrolling volunteers at Duke University in Durham, North Carolina. This Phase 1 trial will test the experimental

vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response.”

Here is Pfizer CEO **Albert Bourla** predicting this new technology will be available for deployment by flu season 2023.

To the non-immunocompromised, of course — an inconvenient truth, so to speak, for all of the biomedical profiteers — the flu presents no real risk. A strong immune system, as conferred by proper eating habits, exercising, and vitamin D exposure, is well enough to combat the flu.

But, then again, non-patentable vitamin D from the sun is not going to generate executive bonuses or hearty kickbacks to NIH bureaucrats, now is it?

Perhaps this is why [Bill Gates and Co. want to blot out the sun](#).

*

Note to readers: Please click the share button above. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

This article was originally published on [Armageddon Prose](#).

Ben Bartee, author of [Broken English Teacher: Notes From Exile](#), is an independent Bangkok-based American journalist with opposable thumbs. He is a regular contributor to Global Research.

Featured image is from Children's Health Defense

The original source of this article is Global Research
Copyright © [Ben Bartee](#), Global Research, 2023

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Ben Bartee](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca